Ascendis Pharma AS PT Raised to 182.00 - MarketBeat
| A1SN34 Stock | BRL 56.82 0.00 0.00% |
About 55% of Ascendis Pharma's investor base is interested to short. The analysis of current outlook of investing in Ascendis Pharma AS suggests that many traders are impartial regarding Ascendis Pharma's prospects. The current market sentiment, together with Ascendis Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Ascendis Pharma AS stock news signals to limit their universe of possible portfolio assets.
Ascendis |
Ascendis Pharma AS PT Raised to 182.00 MarketBeat
Read at news.google.com
 |
Ascendis Pharma Fundamental Analysis
We analyze Ascendis Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascendis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascendis Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Ascendis Pharma is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Ascendis Pharma AS Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ascendis Pharma stock to make a market-neutral strategy. Peer analysis of Ascendis Pharma could also be used in its relative valuation, which is a method of valuing Ascendis Pharma by comparing valuation metrics with similar companies.
Peers
Ascendis Pharma Related Equities
| P1EA34 | Healthpeak Properties | 0.52 | ||||
| ADPR34 | Automatic Data | 0.00 | ||||
| W1MG34 | Warner Music | 0.73 | ||||
| TTEN3 | Tres Tentos | 1.43 | ||||
| MRFG3 | Marfrig Global | 1.81 |
Complementary Tools for Ascendis Stock analysis
When running Ascendis Pharma's price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |